0
Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics' experimental cell therapy for a fatal inherited disease that weakens muscle, the health regulator said
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)